DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry

The life science industry increasingly demands for Europe-wide transport solutions which are able to guarantee product integrity. Being able to offer this, strengthens a global market position. Thus, DHL Freight has been developing the unique DHL COLDCHAIN network.

DHL COLDCHAIN supports its customers by efficient, flexible and most reliable transport solutions along the entire supply chain. By shaping this innovative solution across Europe, DHL Freight becomes the preferred logistics partner for the life science industry.

DHL comprises long-term experience and knowledge gathered by working for major life science companies for numerous years.DHL has been constantly listening to its customers in all major layers in the market sector, and learned their specific requirements and demands concerning transport solutions. Following these guidelines the DHL COLDCHAIN services have been developed. DHL COLDCHAIN is a dedicated, fully monitored and temperature controlled LTL network offering the best possible treatment for sensitive products of this market sector.

DHL COLDCHAIN meets all requirements of the industry in terms of temperature control, security and handling. Its services cover the range of refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius).

International temperature controlled network
Throughout Europe, DHL Freight built the infrastructure for demanding products of pharmaceutical and life science industry. A fleet of refrigerated trucks is at your disposal at any time, and ensures the sensitive goods are constantly treated at the right temperature.

Throughout the journey, the temperature of the pharmaceuticals is continuously measured and transmitted via GPS.With our state of-the-art IT tools, this allows each customer to track the status and temperature of all shipments during the entire journey. In addition, all warehouses and cross docking stations are specifically equipped to guarantee continuous temperature control. Of course, they meet all GDP requirements (Good Distribution Practice). In the extension of DHL Freight network of branch offices and cross-docking stations, DHL COLDCHAIN provides the shortest possible lead-times. As an advantage, DHL COLDCHAIN is an LTL (less than truck load) service with fixed departure schedules. By these choices, our customers benefit from our flexibility and costeffectiveness. Even for smaller volumes.

Services

  • Unique DHL COLDCHAIN network across Europe and beyond
  • LTL consolidation service
  • Temperature controlled services for refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius)
  • Top quality handling and security services
  • GPS security surveillance
  • Scheduled departures and deliveries
  • Short lead times
  • Central booking and administration
  • Online tracking & tracing
  • Temperature data recording

For further information, please contact:

DHL Freight
Life Science Competence Center
DHL Logistics (Switzerland) Ltd
St. Jakobs-Strasse 224
4052 Basle
Switzerland
Telephone +41 61 315 9191
www.dhl.ch

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...